Skip to main content
. Author manuscript; available in PMC: 2018 Oct 9.
Published in final edited form as: Sci Transl Med. 2018 May 16;10(441):eaap8307. doi: 10.1126/scitranslmed.aap8307

Figure 1: Metarrestin reduces PNCs at a sub-micromolar concentration and inhibits invasion of cancer cells.

Figure 1:

(A) Metarrestin concentration-response curve against PNC prevalence in PC3M-GFP-PTB cells (yellow, PC3M, has a PNC prevalence of 75-85% in the absence of treatment) and cytotoxicity as measured by cellular ATP (CellTiter Glo) (blue). Shown above are representative PTB-GFP images for cells at the indicated concentrations (arrowheads indicate PNCs) (scale bar = 5 μm). (B) The structure of metarrestin. (C) 1 μM metarrestin was effective at reducing PNCs in a range of cancer cell lines (p<0.05 for PNC reduction in all cell lines; the list of cell lines is in table S1). (D) Metarrestin inhibits Matrigel invasion at below micromolar concentrations (0.6 μM) within 24 hours of treatment (* p<0.05 and ** p<0.01 in comparison to DMSO). (E) Metarrestin at 1 μM impacts cell growth in cancer cell line PC3M but not in normal fibroblasts (GM02153) (arrow indicates the time of medium change). * P < 0.05, ** P < 0.01.